Day One Biopharmaceuticals, Inc.DAWNNASDAQ

Revenue (LTM)

$158M

+20.6% YoY

Net Income (LTM)

$-107M

-12.4% YoY

Free Cash Flow

$-104M

Revenue CAGR (5Y)

—

Marginsdeclining

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	131	158↑20.6%
Gross Profit	-0	-1↓166.8%	-0↑27.9%	126↑32967.4%	141↑12.0%
Operating Income	-73	-147↓102.0%	-206↓40.3%	-217↓5.4%	-128↑41.2%
Net Income	-71	-142↓101.3%	-189↓32.9%	-95↑49.5%	-107↓12.4%
EBITDA	-73	-142↓95.2%	-189↓33.1%	-86↑54.2%	-106↓22.6%
EPS Diluted	-1.14	-2.02↓77.2%	-2.37↓17.3%	-1.02↑57.0%	-1.04↓2.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	284	85↓70.0%	231↑170.7%	125↓45.9%	197↑57.7%
Total Current Assets	289	348↑20.2%	375↑7.9%	562↑49.8%	485↓13.7%
Total Assets	290	349↑20.4%	376↑7.7%	583↑55.0%	508↓12.9%
Total Current Liabilities	9	17↑91.9%	30↑77.6%	73↑148.9%	61↓17.6%
Total Liabilities	9	17↑96.3%	30↑73.3%	80↑171.2%	67↓16.7%
Total Equity	281	332↑18.1%	347↑4.4%	503↑45.1%	441↓12.3%
Total Debt	0	1↑269.5%	0↓49.8%	3↑537.7%	3↑7.3%
Net Debt	-284	-84↑70.3%	-230↓172.8%	-122↑46.9%	-194↓58.8%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-49	-110↓126.4%	-147↓33.7%	-78↑46.8%	-104↓32.8%
Capital Expenditure	-8	-0↑99.7%	-3↓12300.0%	-2↑32.7%	-0↑85.2%
Free Cash Flow	-57	-110↓94.4%	-150↓36.6%	-80↑46.5%	-104↓29.6%
Stock-Based Comp	13	27↑104.5%	39↑44.4%	48↑22.7%	44↓8.0%
Net Change in Cash	241	-199↓182.7%	146↑173.1%	-106↓172.7%	72↑168.1%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance